{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105011","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.362970+00:00","generated_at":"2026-05-17T17:33:34.758195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough","bullets":["Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).","LCQ Total Score increased 3.4 points (108 mg) and 3.7 points (54 mg); 1.3-point increase is clinically meaningful.","Completed $115M underwritten offering; cash and securities $203.9M, runway into 2029.","R&D expenses $9.4M (down from $10.0M); G&A $4.3M (up from $3.3M); net loss $12.3M.","Plans to request End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 start expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105011","json":"https://secwatch.observer/filing/0000950170-25-105011.json","markdown":"https://secwatch.observer/filing/0000950170-25-105011.md","text":"https://secwatch.observer/filing/0000950170-25-105011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/0000950170-25-105011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/trvi-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:33:34.758195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}